Diabetes mellitus induced by immune checkpoint inhibitors.
Diabetes Metab Res Rev
; 37(1): e3366, 2021 01.
Article
em En
| MEDLINE
| ID: mdl-32543027
ABSTRACT
Immune checkpoint inhibitors (ICIs) are widely used in oncology for their favourable antitumor efficacy. ICI therapy is associated with a unique toxicity profile known as immune-related adverse events (irAEs). One such irAE is ICI-related diabetes mellitus (DM), which is relatively uncommon but can become extremely severe, leading to irreversible impairment of ß-cells, and even lead to death if not promptly recognised and properly managed. The precise mechanisms of ICI-related DM are not well understood. In this review, we summarise the clinical characteristics, pathophysiology, and management of this adverse effect caused by ICI therapy. Deeper investigation of ICI-related DM may contribute to elucidate the molecular mechanisms of classical type 1 DM.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus
/
Inibidores de Checkpoint Imunológico
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article